Skip to main content

Table 3 The differentially overexpressed genes and their significance in refractory breast cancer patients

From: Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients

No. Genes P value No. Genes P value
1 AKT1 0.30 29 MAP2K4 0.76
2 AKT2 0.78 30 MAP2K7 0.28
3 AKT3 0.18 31 MAP3K2 0.22
4 ARAF 0.98 32 MAPK1 0.26
5 ATF1 0.25 33 MAPK3 0.15
6 ATF2 0.56 34 MAPK8 0.54
7 BAD 0.86 35 MKNK1 0.05
8 BCL2 0.80 36 MMP7 0.67
9 BRAF 0.37 37 NCK2 0.18
10 CHUK 0.50 38 NFATC3 0.71
11 COL1A1 0.06 39 NFKB1 0.36
12 CSNK2A1 0.57 40 NRAS 0.31
13 DUSP1 0.32 41 PDGFRA 0.35
14 EGF 0.35 42 PDPK1 0.43
15 EGFR 0.15 43 PIK3CA 0.79
16 EIF4E 0.61 44 PIK3R1 0.30
17 FN1 0.02 45 PPP2CA 0.34
18 FOS 0.43 46 PRKCA 0.66
19 FOXO3 0.37 47 PTEN 0.34
20 GAB1 0.04 48 RPS6KA5 0.43
21 GRB2 0.26 49 RPS6KB1 0.13
22 GSK3A 0.38 50 SHC1 0.16
23 GSK3B 0.36 51 STAT1 0.53
24 IKBKB 0.82 52 TP53 0.21
25 IL2 0.62 53 B2M 0.66
26 JAK1 0.001 54 GAPDH 0.90
27 KRAS 0.53 55 RPLP0 0.38
28 MAP2K1 0.75 56 HGDC 0.12